Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 46

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 46
---
 realized, or if the Merger and integration-related costs related to the Merger are greater than expected. The market price of MIRA Common Stock may also decline if MIRA does not achieve the anticipated benefits of the Merger as rapidly or to the extent expected by financial or industry analysts or if the effects of the Merger on MIRA’s financial position, results of operations or cash flows are not otherwise consistent with the expectations of financial or industry analysts. The issuance of shares of MIRA Common Stock in the Merger could on its own have the effect of depressing the market price for MIRA Common Stock. In addition, some SKNY stockholders may decide not to continue to hold the shares of MIRA Common Stock they receive as a result of the Merger, and any such sales of MIRA Common Stock could have the effect of depressing the market price for MIRA Common Stock. Moreover, general fluctuations in stock markets could have a material adverse effect on the market for, or liquidity of, MIRA Common Stock, regardless of the actual operating performance of MIRA or the surviving company following the completion of the Merger.

If MIRA is found to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical for us to continue our business as contemplated and could adversely affect our business, financial condition or results of operations.

We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities; or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test. SKNY is the beneficial owner of shares of Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), or Telomir. Accordingly, following the completion of the Merger, we will own such shares of Telomir, and potentially be in violation of the ICA 40% Test.

We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvest